Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Leases (2023 - 2026)

bioAffinity Technologies has reported Current Leases over the past 4 years, most recently at $80241.0 for Q1 2026.

  • Quarterly Current Leases fell 38.44% to $80241.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $80241.0 through Mar 2026, down 38.44% year-over-year, with the annual reading at $139490.0 for FY2025, 9.41% up from the prior year.
  • Current Leases was $80241.0 for Q1 2026 at bioAffinity Technologies, down from $139490.0 in the prior quarter.
  • Over five years, Current Leases peaked at $387780.0 in Q3 2024 and troughed at $80241.0 in Q1 2026.
  • The 4-year median for Current Leases is $133239.0 (2025), against an average of $187697.0.
  • The largest YoY upside for Current Leases was 34.89% in 2025 against a maximum downside of 64.96% in 2025.
  • A 4-year view of Current Leases shows it stood at $94708.0 in 2023, then surged by 34.62% to $127498.0 in 2024, then grew by 9.41% to $139490.0 in 2025, then crashed by 42.48% to $80241.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Current Leases are $80241.0 (Q1 2026), $139490.0 (Q4 2025), and $136197.0 (Q3 2025).